Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02343406
Title ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma
Acronym INTELLANCE-2
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS


No variant requirements are available.